Sanraku-ocean Co., Ltd.

Sanraku Incorporated

Akihiro Yoshimoto

Tomio Takeuchi

Hamao Umezawa

Tomoyuki Ishikura

Toshikazu Oki

Taiji Inui

Tsutomu Sawa

Yoshio Watanabe

Osamu Jodo

Kageaki Kouno

Yasue Matsuzawa

Rokuro Okamoto

Hiroyasu Tobe

Yukio Takatsuki

Hiroshi Naganawa

Hamao Umezawa, Deceased

Katsuro Kubo

Shizuka Fujii

This invention relates to a process for preparing an antibiotic D788-7 wherein, after culturing carborubicin-producing bacteria, the obtained culture liquid is extracted in acidic conditions while stirring to be absorbed to synthetic resin, followed by desorption from the resin and elution with acetone and the resulting acetone solution containing carborubicin is converted into an antibiotic D788-7 by photo radiation, for obtaining D788-7 in the purified form from the reaction solution. The production yield for D788-7 is extremely high and its use as an antitumor agent can be made possible.

Process for preparing antibiotics D788-7

Disclosed are anthracycline antibiotics of a formula (I): ##STR1## in which R.sup.1 and R.sup.2 are hydroxyl groups, R.sup.3 is ethyl group, R.sup.4 is methoxycarbonyl group and X represents daunosamine-rhodenose or daunosamine-deoxyfucose; or

Anthracycline antibiotics

New anthracycline antibiotics of a formula (I) are provided, which are usable as an anticancer agent ##STR1## (where R represents a hydrogen atom or a hydroxyl group). The antibiotics (I) can be produced by incubation of a dye-nonproductive or hardly dye-productive mutant strain which has an ability of converting .alpha.-citromycinone or .beta.-isorhodomycinone into the antibiotics (I), in the presence of .alpha.-citromycinone or .beta.-isorhodomycinone in a pertinent nutrient medium.

Anthracycline antibiotics DCP-1 and 2

The antibiotics designated obelmycins exhibit high proliferation inhibiting action against leukemia cells and are effective as anti-cancer agents.

Novel anthracycline antibiotics

Novel anthracycline antibiotics characteristic of Ring A of the anthracycline skeleton are produced by microorganisms belonging to the genus Streptomyces and are useful as anti-cancer agents. The antibiotics designated D-788-6 to -10 are shown by general formula: ##STR1## wherein Y represents a group shown by: ##STR2##

This invention is to provide a new microbial process for producing daunomycin by a mutant strain belonging to the genus Streptomyces.

Process for producing daunomycin

New anthracycline compounds, 2-hydroxyaclacinomycin B having potent antitumor activity and lower toxicity, and a process for producing 2-hydroxyaclacinomycins A, B, and N by fermentation.

New anthracycline derivatives, .beta.-rhodomycinone-RDA, .beta.-rhodomycinone-RDRs and .beta.-rhodomycinone-RD having potent anticancer activities and lower toxicities and a process for the production thereof by reduction or hydrolysis of .beta.-rhodomycinone-RDC are disclosed.

Anthracycline derivatives of .beta.-rhodomycinone glycosides

Disclosed are an antitumor compound having the chemical structure ##STR1## or its acid addition salts; and its preparation method which consists of treating a compound represented by the chemical structure ##STR2## wherein

Anthracycline antibiotic compounds

New anthracycline compounds, 2-hydroxyaclacinomycin A having potent antitumor activity and lower toxicity, 2-hydroxyaklavinone as an useful precursor for producing anthracycline glycosides, and a process for the production thereof by microbial conversion method are disclosed.

2-Hydroxyaclacinomycin A and 2-hydroxyaklavinone and process for

The invention is to provide a new process for producing daunomycin and baumycins having potent antitumor activity and low toxicity by microbial conversion of anthracyclinones such as aklavinone and .epsilon.-rhodomycinone.

Process for producing anthracycline glycosides

New anthracycline glycoside derivatives of rhodomycin-group, .epsilon.-rhodomycin RDC, .epsilon.-isorhodomycin RDC, .beta.-rhodomycin RDC, .gamma.-rhodomycin RDC, .gamma.-rhodomycin RDRs and .beta.-pyrromycin RDC having potent anticancer activities and lower toxicities and a process for the production thereof by microbiological conversion method are disclosed.

Rhodomycin antibiotics

New anthracycline derivatives, 1-hydroxy-13-dihydrodaunomycin and N-formyl-1-hydroxy-13-dihydrodaunomycin are produced by microbial transformation of .epsilon.-pyrromycinone and .epsilon.-isorhodomycinone with daunomycin-producing streptomyces and their mutants. The derivatives herein are useful as cancer chemotherapeutic agents.

Growing community of inventors

Fujisawa, Japan

Akihiro Yoshimoto